456 related articles for article (PubMed ID: 21845838)
1. [Recombinant adeno-associated virus vector related impurities].
Diao Y; Wang Q; Xiao W; Xu R
Sheng Wu Gong Cheng Xue Bao; 2011 May; 27(5):717-23. PubMed ID: 21845838
[TBL] [Abstract][Full Text] [Related]
2. Novel strategy for generation and titration of recombinant adeno-associated virus vectors.
Shiau AL; Liu PS; Wu CL
J Virol; 2005 Jan; 79(1):193-201. PubMed ID: 15596815
[TBL] [Abstract][Full Text] [Related]
3. [Capsid assembly and DNA encapsidation of adeno-associated virus].
Wang Q; Lü Y; Li Z; Diao Y; Xu R
Sheng Wu Gong Cheng Xue Bao; 2011 Apr; 27(4):531-8. PubMed ID: 21847986
[TBL] [Abstract][Full Text] [Related]
4. Purification of recombinant adeno-associated virus type 8 vectors by ion exchange chromatography generates clinical grade vector stock.
Davidoff AM; Ng CY; Sleep S; Gray J; Azam S; Zhao Y; McIntosh JH; Karimipoor M; Nathwani AC
J Virol Methods; 2004 Nov; 121(2):209-15. PubMed ID: 15381358
[TBL] [Abstract][Full Text] [Related]
5. Production and purification of recombinant adeno-associated vectors.
Wang L; Blouin V; Brument N; Bello-Roufai M; Francois A
Methods Mol Biol; 2011; 807():361-404. PubMed ID: 22034039
[TBL] [Abstract][Full Text] [Related]
6. Novel tools for production and purification of recombinant adenoassociated virus vectors.
Grimm D; Kern A; Rittner K; Kleinschmidt JA
Hum Gene Ther; 1998 Dec; 9(18):2745-60. PubMed ID: 9874273
[TBL] [Abstract][Full Text] [Related]
7. Identification of a replication-defective herpes simplex virus for recombinant adeno-associated virus type 2 (rAAV2) particle assembly using stable producer cell lines.
Toublanc E; Benraiss A; Bonnin D; Blouin V; Brument N; Cartier N; Epstein AL; Moullier P; Salvetti A
J Gene Med; 2004 May; 6(5):555-64. PubMed ID: 15133766
[TBL] [Abstract][Full Text] [Related]
8. [Production and purification of helper free recombinant adeno-associated virus 2].
Li GL; Wang RZ; Wang X; Dou WC; Zhang B; Tian SQ; Ren ZY; Su CB
Zhonghua Yi Xue Za Zhi; 2003 Jul; 83(14):1255-8. PubMed ID: 12930642
[TBL] [Abstract][Full Text] [Related]
9. Generation of a high-capacity hybrid vector: packaging of recombinant adenoassociated virus replicative intermediates in adenovirus capsids overcomes the limited cloning capacity of adenoassociated virus vectors.
Gonçalves MA; Pau MG; de Vries AA; Valerio D
Virology; 2001 Sep; 288(2):236-46. PubMed ID: 11601895
[TBL] [Abstract][Full Text] [Related]
10. Scaleable chromatographic purification process for recombinant adeno-associated virus (rAAV).
O'Riordan CR; Lachapelle AL; Vincent KA; Wadsworth SC
J Gene Med; 2000; 2(6):444-54. PubMed ID: 11199265
[TBL] [Abstract][Full Text] [Related]
11. High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 Rep and Cap.
Conway JE; Rhys CM; Zolotukhin I; Zolotukhin S; Muzyczka N; Hayward GS; Byrne BJ
Gene Ther; 1999 Jun; 6(6):986-93. PubMed ID: 10455400
[TBL] [Abstract][Full Text] [Related]
12. Vector characterization methods for quality control testing of recombinant adeno-associated viruses.
Wright JF; Zelenaia O
Methods Mol Biol; 2011; 737():247-78. PubMed ID: 21590401
[TBL] [Abstract][Full Text] [Related]
13. A stable cell line carrying adenovirus-inducible rep and cap genes allows for infectivity titration of adeno-associated virus vectors.
Clark KR; Voulgaropoulou F; Johnson PR
Gene Ther; 1996 Dec; 3(12):1124-32. PubMed ID: 8986439
[TBL] [Abstract][Full Text] [Related]
14. Characterizing clearance of helper adenovirus by a clinical rAAV1 manufacturing process.
Thorne BA; Quigley P; Nichols G; Moore C; Pastor E; Price D; Ament JW; Takeya RK; Peluso RW
Biologicals; 2008 Jan; 36(1):7-18. PubMed ID: 17644406
[TBL] [Abstract][Full Text] [Related]
15. Optimised helper virus-free production of high-quality adeno-associated virus vectors.
Drittanti L; Jenny C; Poulard K; Samba A; Manceau P; Soria N; Vincent N; Danos O; Vega M
J Gene Med; 2001; 3(1):59-71. PubMed ID: 11269337
[TBL] [Abstract][Full Text] [Related]
16. Production of recombinant adeno-associated virus vectors.
Zolotukhin S
Hum Gene Ther; 2005 May; 16(5):551-7. PubMed ID: 15916480
[TBL] [Abstract][Full Text] [Related]
17. Separating Empty and Full Recombinant Adeno-Associated Virus Particles Using Isocratic Anion Exchange Chromatography.
Dickerson R; Argento C; Pieracci J; Bakhshayeshi M
Biotechnol J; 2021 Jan; 16(1):e2000015. PubMed ID: 33002276
[TBL] [Abstract][Full Text] [Related]
18. [Cellular immunotoxicity of rAAV gene medicine and possible solutions].
Diao Y; Wang QZ; Xiao WD; Xu RA
Yao Xue Xue Bao; 2010 Sep; 45(9):1071-7. PubMed ID: 21351561
[TBL] [Abstract][Full Text] [Related]
19. Factors influencing recombinant adeno-associated virus production.
Salvetti A; Orève S; Chadeuf G; Favre D; Cherel Y; Champion-Arnaud P; David-Ameline J; Moullier P
Hum Gene Ther; 1998 Mar; 9(5):695-706. PubMed ID: 9551617
[TBL] [Abstract][Full Text] [Related]
20. Immunity to adeno-associated virus vectors in animals and humans: a continued challenge.
Zaiss AK; Muruve DA
Gene Ther; 2008 Jun; 15(11):808-16. PubMed ID: 18385765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
